Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Beam Therapeutics (BEAM) has tangible clinical progress in AATD and multiple programs moving into pivotal work. With a market cap near $2.5B, a supportive balance sheet, and visible catalysts, we prefer a mid-term long swing to capture follow-through from clinical data and investor rotation into gene editing—while protecting capital with a defined …
Cartesian Therapeutics announced encouraging additional retreatment data for Descartes-08, its investigational CAR-T cell therapy targeting myasthenia gravis (MG). Data from five retreated patients showed sustained and improved symptom relief up to 12 months after retreatment, with a mean 6.6-point reduction in MG-ADL scores. The therapy was well t…
Cellectar Biosciences presented data from a subset analysis of its Phase 2 CLOVER WaM trial showing high response rates in Waldenström Macroglobulinemia patients refractory or resistant to BTK inhibitor therapy using iopofosine I 131. The drug demonstrated a major response rate of 79.2%, overall response rate of 87.5%, and duration of response exce…
Optimi Health Corp., a publicly traded commercial-stage psychedelic drug manufacturer, appointed Melanie Pump, a seasoned financial executive with 25+ years of experience in technology and emerging companies, to its Board of Directors. The company aims to leverage her expertise as it advances its position in the regulated psychedelic pharmaceutical…
Cognition Therapeutics announced a Type C meeting scheduled with the FDA to align on primary endpoints for its planned Phase 3 trial of Zervimesine (CT1812) targeting psychosis symptoms in people with dementia with Lewy bodies (DLB). The company seeks to finalize the trial design focused on hallucinations and delusions and aims to offer a disease-m…
FTI Consulting has appointed Jeffrey Hecht as Senior Managing Director to lead its Private Equity Tax and Advisory Services practice. Leveraging his extensive experience, Hecht will drive growth and enhance service offerings for private equity and multi-asset managers, focusing on transactions, fund formation, tax planning, and compliance.
Mixed Martial Arts Group Limited (NYSE American: MMA), operating as MMA.INC, announced over $800,000 in additional annualized cash operating cost reductions since July 1, 2026, bringing total reductions to over $2.51 million. These reductions stem from technology delivery, AI-supported workflows, and operational discipline, enabling a leaner cost b…
Medicus Pharma has submitted an optimized seamless Phase 2b/3 registration-intent protocol for its investigational drug Teverelix®, a next-generation GnRH antagonist, to the FDA. The protocol targets advanced prostate cancer patients at increased cardiovascular risk and aims to create a more capital-efficient, partner-ready development pathway. Thi…
DeFi Technologies Inc., through its subsidiary Valour, has launched the Valour Zcash (ZEC) SEK Exchange Traded Product (ETP) on the Spotlight Stock Market, enabling investors to gain regulated access to the privacy-focused digital asset Zcash via traditional brokerage accounts. This product expands Valour’s portfolio of over 100 digital asset ETPs …
Nu Holdings has turned explosive user growth into real profitability and cash generation. At roughly $59 billion market cap and trading near $12.25, the stock prices in slower expansion than the company is delivering. This trade idea outlines a long entry, targets and risks for a long-term (180 trading days) position that backs the thesis with rece…
Polar Power announced a trial order for 50 propane-fueled DC generators from a major Tier 1 telecom operator in Southeast Asia, powering off-grid cell sites. This initial step could lead to a potential five-year program deploying up to 2,500 generators, representing approximately $60 million in revenue. The company's propane-based DC generators pro…
TruGolf Holdings, Inc. announced that its executives along with Polymath Research Inc.'s CFO will present at The ThinkEquity Conference in New York. The presentation will focus on TruGolf’s established golf technology business and their expansion into tokenized financial infrastructure through the proposed acquisition of Polymath, a company special…
uniQure announced additional data from its ongoing Phase I/II trials of ifezuntirgene inilparvovec for Huntington's disease, demonstrating sustained slowing of disease progression at 36 and 48 months post-treatment. The gene therapy showed dose-dependent benefits on key clinical measures with a favorable safety profile, supporting its recent Biolog…
Immix Biopharma, a Nasdaq-listed biotech company focused on AL Amyloidosis treatments, announced the pricing of an underwritten offering of approximately 11.36 million shares at $11.00 each, raising gross proceeds of $125 million. The funds will be used primarily to advance development of its lead CAR-T therapy, NXC-201, and for general corporate p…
Unicycive Therapeutics announced the resubmission of its New Drug Application for oxylanthanum carbonate, an investigational treatment for hyperphosphatemia in dialysis patients with chronic kidney disease. The resubmission includes new Chemistry, Manufacturing, and Controls data from a different FDA-compliant drug product manufacturing vendor, alo…
Ocugen, Inc., a biotech company developing gene therapies for blindness diseases, will have its executive leadership present at two October 2026 investor and industry conferences focused on life sciences financing and gene therapy commercialization.
BeyondSpring announced FDA Fast Track designation for Plinabulin combined with docetaxel to treat advanced non-squamous NSCLC patients post immune checkpoint inhibitors and chemotherapy. The company also entered a strategic transaction selling its majority stake in its Chinese subsidiary to an investor who will fund about half of the global Phase 3…
Invivyd announced positive topline results from its LIBERTY Phase 3 study showing that its monoclonal antibody candidate VYD2311 exhibits clinically and statistically superior safety and tolerability compared to an mRNA-based COVID-19 vaccine. The study also found that co-administration of VYD2311 with the mRNA vaccine did not reduce vaccine effect…
Gold Fields looks like a tactical long after recent weakness: a successful ramp at Salares Norte should underpin production and cash flow, valuation is reasonable at a $31.2B market cap and 8.2x P/E, and the stock is technically oversold (RSI ~30). That said, government/regulatory risk at Tarkwa and potential M&A/capital-discipline questions could …
Iovance Biotherapeutics increased its full year 2026 revenue guidance to $410-$420 million, up $55 million from prior guidance, driven by strong U.S. demand for its cancer therapies Amtagvi (lifileucel) and Proleukin. The company reported record Q2 revenues and expects continued growth fueled by expanding authorized treatment centers and progress i…
EVgo Inc., a major US public fast charging network for electric vehicles, announced a next-generation charging system capable of delivering up to 750kW. Developed at their Innovation Lab in California with Delta Electronics, the new charger aims to future-proof the network to meet increasing demand and support faster charging times around 10 minute…
NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies, announced the hiring of Craig Blanchard as Chief Commercial Officer to lead sales and marketing efforts. This strategic move aims to support the anticipated growth in commercial operations and increase patient access to its FDA-cleared IB-Stim device for treatin…
Xanadu Quantum Technologies partnered with Bluefors to create a novel high-performance cryogenic prototype aimed at enabling scalable, modular infrastructure for utility-scale quantum computing data centers. This multi-million dollar collaboration seeks to replace traditional industrial-scale cryoplants with compact, efficient cooling modules that …
Aquestive Therapeutics has appointed Richard Daly, a veteran life sciences executive with over 30 years of experience in pharmaceutical leadership and commercial operations, to its Board of Directors. Daly's expertise is expected to strengthen the company's commercial capabilities as it prepares for the potential FDA approval and launch of Anaphylm…
Nurix Therapeutics announced it has achieved a $7 million research milestone under its collaboration with Pfizer, bringing total payments received under the agreement to $82 million. The partnership focuses on the discovery and development of degrader antibody conjugates (DACs), a next-generation therapeutic modality combining antibody selectivity …
